Trial Watch

References

• Alkan SS. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine. Nat Rev Immunol 2004; 4:153 - 6; http://dx.doi.org/10.1038/nri1265; PMID: 15040588
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317 - 27; http://dx.doi.org/10.1038/nri2744; PMID: 20414205
   PubMed Web of Science ®Google Scholar
• Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997 - 1008; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214; PMID: 23460531
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95 - 106; http://dx.doi.org/10.1038/nrc2051; PMID: 17251916
   PubMed Web of Science ®Google Scholar
• Gray JC, Johnson PW, Glennie MJ. Therapeutic potential of immunostimulatory monoclonal antibodies. Clin Sci (Lond) 2006; 111:93 - 106; http://dx.doi.org/10.1042/CS20060024; PMID: 16831129
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28 - 37; http://dx.doi.org/10.4161/onci.1.1.17938; PMID: 22720209
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; http://dx.doi.org/10.4161/onci.22789; PMID: 23482847
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, et al. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. OncoImmunology 2014; Forthcoming
   Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391 - 400; http://dx.doi.org/10.1038/nrd1381; PMID: 15136787
   PubMed Web of Science ®Google Scholar
• Michielsen AJ, Ryan EJ, O’Sullivan JN. Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. Oncoimmunology 2012; 1:1445 - 7; http://dx.doi.org/10.4161/onci.21318; PMID: 23243624
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235 - 42; http://dx.doi.org/10.1056/NEJMoa011795; PMID: 11807147
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825 - 33; PMID: 9704735
   PubMed Web of Science ®Google Scholar
• Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT. High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. Oncoimmunology 2012; 1:75 - 7; http://dx.doi.org/10.4161/onci.1.1.17825; PMID: 22720216
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24:19 - 28; http://dx.doi.org/10.1016/j.immuni.2005.11.010; PMID: 16413920
   PubMed Web of Science ®Google Scholar
• Hubert P, Amigorena S. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy. Oncoimmunology 2012; 1:103 - 5; http://dx.doi.org/10.4161/onci.1.1.17963; PMID: 22720225
   PubMed Web of Science ®Google Scholar
• Houot R, Kohrt H, Levy R. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 2012; 1:957 - 8; http://dx.doi.org/10.4161/onci.19974; PMID: 23162770
   PubMed Web of Science ®Google Scholar
• Kute T, Stehle JR Jr., Ornelles D, Walker N, Delbono O, Vaughn JP. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology 2012; 1:810 - 21; http://dx.doi.org/10.4161/onci.20447; PMID: 23162748
   PubMed Web of Science ®Google Scholar
• Winiarska M, Glodkowska-Mrowka E, Bil J, Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed) 2011; 16:277 - 306; http://dx.doi.org/10.2741/3688; PMID: 21196171
   PubMed Web of Science ®Google Scholar
• Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20:34 - 50; http://dx.doi.org/10.1038/cr.2009.139; PMID: 20010915
   PubMed Web of Science ®Google Scholar
• Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729 - 40; PMID: 19730437
   PubMed Web of Science ®Google Scholar
• Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:502 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-07-1509; PMID: 18223225
   PubMed Web of Science ®Google Scholar
• Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. Oncoimmunology 2013; 2:e24677; http://dx.doi.org/10.4161/onci.24677; PMID: 23894722
   PubMedGoogle Scholar
• Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120:781 - 7; http://dx.doi.org/10.1002/ijc.22370; PMID: 17096332
   PubMed Web of Science ®Google Scholar
• Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19:1858 - 72; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426; PMID: 23444227
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74 - 88; http://dx.doi.org/10.1016/j.immuni.2013.06.014; PMID: 23890065
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:2453 - 63; http://dx.doi.org/10.1200/JCO.2002.11.076; PMID: 12011122
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259 - 66; PMID: 10942366
   PubMed Web of Science ®Google Scholar
• Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11:852 - 63; http://dx.doi.org/10.1038/nri3108; PMID: 22116087
   PubMed Web of Science ®Google Scholar
• Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4:336 - 47; http://dx.doi.org/10.1038/nri1349; PMID: 15122199
   PubMed Web of Science ®Google Scholar
• Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 2012; 1:544 - 6; http://dx.doi.org/10.4161/onci.19442; PMID: 22754781
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Svane IM, Andersen MH. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells. Oncoimmunology 2013; 2:e23991; http://dx.doi.org/10.4161/onci.23991; PMID: 23734334
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223 - 5; http://dx.doi.org/10.4161/onci.21335; PMID: 23243584
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009; 10:1185 - 92; http://dx.doi.org/10.1038/ni.1790; PMID: 19783989
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239 - 45; http://dx.doi.org/10.1038/ni1443; PMID: 17304234
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261 - 8; http://dx.doi.org/10.1038/85330; PMID: 11224527
   PubMed Web of Science ®Google Scholar
• Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009; 9:568 - 80; http://dx.doi.org/10.1038/nri2604; PMID: 19629084
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2:850 - 61; http://dx.doi.org/10.1038/nrc928; PMID: 12415255
   PubMed Web of Science ®Google Scholar
• Joncker NT, Raulet DH. Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev 2008; 224:85 - 97; http://dx.doi.org/10.1111/j.1600-065X.2008.00658.x; PMID: 18759922
   PubMed Web of Science ®Google Scholar
• Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008; 224:70 - 84; http://dx.doi.org/10.1111/j.1600-065X.2008.00660.x; PMID: 18759921
   PubMed Web of Science ®Google Scholar
• Withers DR, Gaspal FM, Bekiaris V, McConnell FM, Kim M, Anderson G, Lane PJ. OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev 2011; 244:134 - 48; http://dx.doi.org/10.1111/j.1600-065X.2011.01057.x; PMID: 22017436
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9:271 - 85; http://dx.doi.org/10.1038/nri2526; PMID: 19319144
   PubMed Web of Science ®Google Scholar
• Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004; 4:420 - 31; http://dx.doi.org/10.1038/nri1371; PMID: 15173831
   PubMed Web of Science ®Google Scholar
• Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 2012; 1:458 - 66; http://dx.doi.org/10.4161/onci.19855; PMID: 22754764
   PubMed Web of Science ®Google Scholar
• Shevach EM, Stephens GL. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?. Nat Rev Immunol 2006; 6:613 - 8; http://dx.doi.org/10.1038/nri1867; PMID: 16868552
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3:135 - 42; http://dx.doi.org/10.1038/ni759; PMID: 11812990
   PubMed Web of Science ®Google Scholar
• Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14:715 - 25; http://dx.doi.org/10.1016/S1074-7613(01)00147-9; PMID: 11420042
   PubMed Web of Science ®Google Scholar
• Schnurr M, Duewell P. Breaking tumor-induced immunosuppression with 5′-triphosphate siRNA silencing TGFβ and activating RIG-I. Oncoimmunology 2013; 2:e24170; http://dx.doi.org/10.4161/onci.24170; PMID: 23762798
   PubMedGoogle Scholar
• Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2:46 - 53; http://dx.doi.org/10.1038/nri704; PMID: 11905837
   PubMed Web of Science ®Google Scholar
• Pickup M, Novitskiy S, Moses HL. The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 2013; 13:788 - 99; http://dx.doi.org/10.1038/nrc3603; PMID: 24132110
   PubMed Web of Science ®Google Scholar
• Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10:415 - 24; http://dx.doi.org/10.1038/nrc2853; PMID: 20495575
   PubMed Web of Science ®Google Scholar
• LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, Wheeler RH. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst 1988; 80:932 - 6; http://dx.doi.org/10.1093/jnci/80.12.932; PMID: 3398068
   PubMed Web of Science ®Google Scholar
• Lobuglio AF, Saleh M, Peterson L, Wheeler R, Carrano R, Huster W, Khazaeli MB. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma 1986; 5:Suppl 1 S117 - 23; PMID: 3488950
   PubMedGoogle Scholar
• Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45:5910 - 3; PMID: 4053061
   PubMed Web of Science ®Google Scholar
• Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Häyry P, Koprowski H. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982; 1:762 - 5; http://dx.doi.org/10.1016/S0140-6736(82)91811-6; PMID: 6121224
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12:991 - 1045; http://dx.doi.org/10.1146/annurev.iy.12.040194.005015; PMID: 8011301
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301 - 5; http://dx.doi.org/10.1126/science.1071059; PMID: 11951032
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155 - 64; http://dx.doi.org/10.1016/S1470-2045(09)70334-1; PMID: 20004617
   PubMed Web of Science ®Google Scholar
• Sosman J, Sznol M, McDermott D, Carvajal RD, Lawrence DP, Topalian SL, et al. Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with advanced melanoma (mel). Ann Oncol 2012; 23: ix367 - 75
   Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167 - 75; http://dx.doi.org/10.1200/JCO.2009.26.7609; PMID: 20516446
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455 - 65; http://dx.doi.org/10.1056/NEJMoa1200694; PMID: 22658128
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443 - 54; http://dx.doi.org/10.1056/NEJMoa1200690; PMID: 22658127
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beeram M, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. . J Clin Oncol 2012; 30:abstr 2512
   Google Scholar
• Tykodi SS, Brahmer JR, Hwu WJ, Chow LQ, Hwu P, Odunsi K, et al. PD-1/PD-L1 pathway as a target for cancer immunotherapy: safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. J Clin Oncol 2012; 30:abstr 2510
   Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25:876 - 83; http://dx.doi.org/10.1200/JCO.2006.08.3311; PMID: 17327609
   PubMed Web of Science ®Google Scholar
• Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95:845 - 8; http://dx.doi.org/10.3324/haematol.2009.008003; PMID: 20133895
   PubMed Web of Science ®Google Scholar
• Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51:228 - 35; http://dx.doi.org/10.3109/10428190903440946; PMID: 20038235
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508 - 16; http://dx.doi.org/10.1053/j.seminoncol.2010.09.008; PMID: 21074066
   PubMed Web of Science ®Google Scholar
• Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008; 1:20; http://dx.doi.org/10.1186/1756-8722-1-20; PMID: 18959794
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, et al. Trial Watch: Peptide vaccines in cancer therapy. OncoImmunology 2013; 2:e26621
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557 - 76; http://dx.doi.org/10.4161/onci.22428; PMID: 23264902
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179 - 88; http://dx.doi.org/10.4161/onci.1.2.19026; PMID: 22720239
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; http://dx.doi.org/10.4161/onci.23510; PMID: 23687621
   PubMed Web of Science ®Google Scholar
• Sherrill B, Wang J, Kotapati S, Chin K. Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br J Cancer 2013; 109:8 - 13; http://dx.doi.org/10.1038/bjc.2013.298; PMID: 23787916
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, et al. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 2013; 62:245 - 56; http://dx.doi.org/10.1007/s00262-012-1330-5; PMID: 22878899
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365 - 6; http://dx.doi.org/10.1056/NEJMc1302338; PMID: 23550685
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75 - 83; http://dx.doi.org/10.1093/annonc/mds213; PMID: 22858559
   PubMed Web of Science ®Google Scholar
• Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr., Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36:382 - 9; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2; PMID: 23924790
   PubMed Web of Science ®Google Scholar
• Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol 2012; 189:3759 - 66; http://dx.doi.org/10.4049/jimmunol.1201529; PMID: 22956585
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122 - 33; http://dx.doi.org/10.1056/NEJMoa1302369; PMID: 23724867
   PubMed Web of Science ®Google Scholar
• Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med 2012; 10:236; http://dx.doi.org/10.1186/1479-5876-10-236; PMID: 23171508
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616 - 22; http://dx.doi.org/10.1200/JCO.2012.44.6112; PMID: 23295794
   PubMed Web of Science ®Google Scholar
• Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer 2013; 108:1998 - 2004; http://dx.doi.org/10.1038/bjc.2013.227; PMID: 23652314
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19:462 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-12-2625; PMID: 23169436
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134 - 44; http://dx.doi.org/10.1056/NEJMoa1305133; PMID: 23724846
   PubMed Web of Science ®Google Scholar
• Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120:4317 - 23; http://dx.doi.org/10.1182/blood-2012-06-437558; PMID: 23002117
   PubMed Web of Science ®Google Scholar
• Benson DM Jr., Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012; 120:4324 - 33; http://dx.doi.org/10.1182/blood-2012-06-438028; PMID: 23033266
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; http://dx.doi.org/10.4161/onci.23033; PMID: 23483678
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 54:277 - 83; http://dx.doi.org/10.3109/10428194.2012.710328; PMID: 22775314
   PubMed Web of Science ®Google Scholar
• Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013; 19:6286 - 95; http://dx.doi.org/10.1158/1078-0432.CCR-13-1320; PMID: 23983255
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53:2136 - 42; http://dx.doi.org/10.3109/10428194.2012.681655; PMID: 22475052
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, Fox BA, et al. OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients. Cancer Res 2013; 73:7189 - 98; http://dx.doi.org/10.1158/0008-5472.CAN-12-4174; PMID: 24177180
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 2013; 31:707 - 13; http://dx.doi.org/10.1007/s10637-012-9866-y; PMID: 22864469
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-08-0237; PMID: 18593931
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678 - 84; http://dx.doi.org/10.1126/science.1224922; PMID: 23019653
   PubMed Web of Science ®Google Scholar
• Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73:2271 - 80; http://dx.doi.org/10.1158/0008-5472.CAN-12-3000; PMID: 23554447
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869 - 83; http://dx.doi.org/10.1038/onc.2011.384; PMID: 21892204
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111 - 34; http://dx.doi.org/10.4161/onci.21494; PMID: 23170259
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; http://dx.doi.org/10.4161/onci.25771; PMID: 24286020
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; http://dx.doi.org/10.4161/onci.24850; PMID: 24073369
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493 - 506; http://dx.doi.org/10.4161/onci.20459; PMID: 22754768
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699 - 716; http://dx.doi.org/10.4161/onci.20696; PMID: 22934262
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894 - 907; http://dx.doi.org/10.4161/onci.20931; PMID: 23162757
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; http://dx.doi.org/10.4161/onci.25238; PMID: 24083080
   PubMed Web of Science ®Google Scholar
• Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy 2013; 5:215 - 29; http://dx.doi.org/10.2217/imt.13.9; PMID: 23444951
   PubMed Web of Science ®Google Scholar
• Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012; 159:58 - 66; http://dx.doi.org/10.1111/j.1365-2141.2012.09251.x; PMID: 22861192
   PubMed Web of Science ®Google Scholar
• Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr Opin Mol Ther 2010; 12:724 - 33; PMID: 21154164
   PubMed Web of Science ®Google Scholar
• Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 2013; 8:e60031; http://dx.doi.org/10.1371/journal.pone.0060031; PMID: 23560068
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; http://dx.doi.org/10.4161/onci.25595; PMID: 24319634
   PubMed Web of Science ®Google Scholar
• Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59:583 - 94; http://dx.doi.org/10.1016/j.jhep.2013.03.033; PMID: 23567086
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9:57 - 63; http://dx.doi.org/10.1038/nrc2541; PMID: 19052556
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51 - 72; http://dx.doi.org/10.1146/annurev-immunol-032712-100008; PMID: 23157435
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860 - 75; http://dx.doi.org/10.1038/nrc3380; PMID: 23151605
   PubMed Web of Science ®Google Scholar
• Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Lenalidomide-based immunochemotherapy. OncoImmunology 2013; 2:e26494
   PubMed Web of Science ®Google Scholar
• Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002; 2:514 - 20; http://dx.doi.org/10.1038/nrc841; PMID: 12094237
   PubMed Web of Science ®Google Scholar
• Eggermont AM. Immunotherapy: Vaccine trials in melanoma -- time for reflection. Nat Rev Clin Oncol 2009; 6:256 - 8; http://dx.doi.org/10.1038/nrclinonc.2009.42; PMID: 19390551
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419 - 26; http://dx.doi.org/10.1038/nature06175; PMID: 17898760
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265 - 77; http://dx.doi.org/10.1038/nrc3258; PMID: 22437871
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; http://dx.doi.org/10.4161/onci.24238; PMID: 23762803
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306 - 15; http://dx.doi.org/10.4161/onci.19549; PMID: 22737606
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013; 31:999 - 1008; http://dx.doi.org/10.1038/nbt.2725; PMID: 24142051
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269 - 81; http://dx.doi.org/10.1038/nri3191; PMID: 22437939
   PubMed Web of Science ®Google Scholar